Gary L. Nelsestuen

Yan Zhang, Alan R. Sinaiko, Gary L. Nelsestuen (2011). Glycoproteins and Glycosylation: Apolipoprotein C3 Glycoforms by top-down MALDI-TOF Mass Spectrometry" methods in Molecular Biology, in press.

D. W. Mahoney, T. M. Therneau, C. J. Heppelmann, L. Higgins, L. M. Benson, R. M. Zenka, P. Jagtap, G. L. Nelsestuen, H. R. Bergen, A. L. Oberg (2011). Relative Quantification: Characterization of bias, variability and fold changes in mass spectrometry data from iTRAQ labeled peptides. J Proteome Res. PMID: 21755926

S. K. Akkina, Y. Zhang, G. L. Nelsestuen, W. S. Oetting and H. N. Ibrahim (2009). Temporal stability of the urinary proteome after kidney transplant: more sensitive than protein composition? Journal of Proteome Research (special issue on temporal and spatial proteomics) 8, 94-103. PMID: 19012427

S. B. Harvey, Y. Zhang, J. Wilson-Grady, T. Monkkonen, G. L. Nelsestuen, R. S. Kasthuri, M. R. Verneris, T. C. Lund, E. Wesley Ely, G. R. Bernard, H. Zeisler, M. Homoncik, B. Jilma, T. Swan, and T. A. Kellogg (2009). The O-glycoside biomaker of Apolipoprotein C3: responsiveness to obesity, bariatric surgery and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs. host disease. Journal of Proteome Research (Special issue on Glycoproteomics) 8, 603-612. PMID: 19055479

R. S. Kasthuri, K. R. McMillan, C. Flood-Urdangarin, S. B. Harvey, J. T. Wilson-Grady, and G. L. Nelsestuen (2007). Correlation of a T45S variant of apolipoprotein C1 with elevated BMI in persons of American Indian and Mexican ancestries International Journal of Obesity, 31(8):1334-6. PMID: 17310220

M.S. Wroblewski, J, T. Wilson-Grady, M.B. Martinez, R. S. Kasthuri, K. R. McMillan, C. Flood-Urdangarin, and G. L. Nelsestuen (2006). A functional polymorphism of apolipoprotein C1 detected by mass spectrometry FEBS Journal 273, 4107-4115. PMID: 16981907

Issued patents: G. L. Nelsestuen, US Patents 7,812,132; 7,750,120; 7,662,923; 7,612,188; 7,553,935; 7,553,934; 7,479,551; 7,294,699; 7,314,917; 7,247,708; 7,160,540; 7,220,837; 6,762,286; 6,747,003; 6,693,075; 6,423,826; 6,017,882; patents pending. Three phase 1 clinical trails have neen successfully completed on various technologies.

S. B. Harvey, M. D. Stone, M.B. Martinez, and G. L. Nelsestuen (2003). Mutagenesis of the gamma-Carboxyglutamic Acid Domain of Human Factor VII to Generate Maximum Enhancement of the Membrane Contact Site. J. Biol. Chem. 278, 8363-8369. PMID: 12506121